Shield Therapeutics plc Sustainability Profile
Shield Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for iron deficiency and related conditions. Founded in 2013, the company has made significant strides in the industry, particularly with its flagship product, Accrufer® (ferric maltol), which offers a unique oral treatment option for patients with iron deficiency anaemia. With a strong presence in both the UK and the US markets, Shield Therapeutics is committed to addressing unmet medical needs through its advanced formulations. The company has achieved notable milestones, including successful regulatory approvals and partnerships that enhance its market position. By prioritising patient-centric solutions, Shield Therapeutics continues to set itself apart in the biopharmaceutical landscape, driving advancements in iron therapy.
DitchCarbon Score
How does Shield Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shield Therapeutics plc's score of 26 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shield Therapeutics plc's reported carbon emissions
Shield Therapeutics plc, headquartered in Great Britain, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Shield Therapeutics may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Shield Therapeutics to consider developing and communicating its climate strategy in the future.
How Carbon Intensive is Shield Therapeutics plc's Industry?
How Carbon Intensive is Shield Therapeutics plc's Location?
Shield Therapeutics plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shield Therapeutics plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
